Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis
The objective of this study is to delineate the cellular adhesion molecule (CAM) profile and plasminogen activator inhibitor type 1 (PAI-1), and their association with metabolic syndrome (MetS) and carbohydrate metabolism biomarkers in psoriasis patients with mild and moderate severity. Sixty-seven patients with psoriasis as well as 102 healthy subjects were recruited. Insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), but not glucose, were significantly higher in psoriasis than in controls. Psoriasis was characterized by increased plasma levels of platelet endothelial cell adhesion molecule 1 (PECAM-1), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin, and PAI-1 as compared with controls. Psoriasis diagnosis could explain 59.0% of CAM and PAI-1 variance, with a particularly strong impact on E-selectin (45.6%), VCAM-1 (32.7%), and PAI-1 (24.8%). Subjects with MetS showed significantly higher E-selectin and PAI-1 than those without MetS. Using VCAM-1, E-selectin, PAI-1 (all positively), and P-selectin (inversely) in a binary regression equation, it was found that 87.6% of all patients were correctly classified with a sensitivity of 92.5% and a specificity of 84.3%. CAM and PAI-1 were correlated with carbohydrate metabolism biomarkers (glucose, insulin, and HOMA-IR). In conclusion, CAM levels are associated with psoriasis diagnosis and MetS may influence E-selectin and PAI-1 concentrations. More studies are needed to verify the causality among these factors, as well as their relation to the different degrees of disease severity.
KeywordsPsoriasis Cellular adhesion molecules Metabolic syndrome Plasminogen activator inhibitor type 1 Carbohydrate metabolism
This study was supported by the National Council of Brazilian Research-CNPq and by Araucária Foundation from the state of Paraná. We thank the University Hospital of State University of Londrina for technical and administrative supports.
This research did not receive any funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its latter amendments or comparable ethical standards.
All the participants included in this study provided written informed consent.
- 2.Bodemer AA. Psoriasis. Integr Med. 2018; 726.e2–38.e2.Google Scholar
- 5.Bautista-Herrera LA, De la Cruz-Mosso U, Morales-Zambrano R, Villanueva-Quintero GD, Hernández-Bello J, Ramírez-Dueñas MG, et al. Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables. Clin Exp Med. 2018;18:229–35.CrossRefGoogle Scholar
- 11.Torres-Alvarez B, Castanedo-Cazares JP, Fuentes-Ahumada C, Moncada B. The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis. J Eur Acad Dermatol Venereol. 2007;21:334–9. https://doi.org/10.1111/j.1468-3083.2006.01916.x.CrossRefPubMedGoogle Scholar
- 12.Bressan AL, Picciani BLS, Azulay-Abulafia L, Fausto-Silva AK, Almeida PN, Cunha KSG, et al. Evaluation of ICAM-1 expression and vascular changes in the skin of patients with plaque, pustular, and erythrodermic psoriasis. Int J Dermatol. 2018;57:209–16. https://doi.org/10.1111/ijd.13883.CrossRefPubMedGoogle Scholar
- 15.Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(657–666):e8.Google Scholar
- 20.da Rosa Franchi Santos LF, Stadtlober NP, Costa Dall’Aqua LG, Scavuzzi BM, Guimarães PM, Flauzino T, et al. Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels. Lupus. 2018;27:380–8. https://doi.org/10.1177/0961203317723716.CrossRefPubMedGoogle Scholar
- 21.de Sá MC, Simão ANC, de Medeiros FA, Iriyoda TMV, Costa NT, Alfieri DF, et al. Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome. Clin Exp Med. 2018;18:495–504. https://doi.org/10.1007/s10238-018-0516-3.CrossRefPubMedGoogle Scholar
- 23.James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20. https://doi.org/10.1001/jama.2013.284427.CrossRefPubMedGoogle Scholar
- 24.Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404.CrossRefGoogle Scholar
- 25.Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80. https://doi.org/10.1161/01.CIR.101.9.975.CrossRefPubMedGoogle Scholar